Reprogrammed macrophages target bone degradation in aging

Researchers have identified MMP9 as the central driver of age-related bone degradation, consistently elevated in elderly individuals. They developed a targeted gene engineering strategy that redirects macrophages to produce anti-MMP9 antibodies through apoptosis-mimicking lipid nanoparticles, enabling systemic neutralization of circulating MMP9. In aged mice, intravenous injection reduced stem cell senescence, accelerated fracture healing, improved cartilage regeneration, and restored the balance between osteoblasts and osteoclasts. The mechanism operates by blocking the senescence-associated secretory phenotype and lowering key markers including p21/MMP3. Although the path to clinical translation remains substantial, this approach demonstrates how mRNA therapies can be precisely redirected toward specific chronic inflammation targets, opening a therapeutic avenue for degenerative bone diseases that currently receive only palliative treatment.